|
DE60205891T2
(de)
|
2001-03-12 |
2006-06-22 |
Intercept Pharmaceuticals, Inc. |
Steroide als agonisten für fxr
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
PT3336097T
(pt)
|
2012-06-19 |
2020-10-29 |
Intercept Pharmaceuticals Inc |
Preparação da forma não cristalina de ácido obeticólico
|
|
NZ708501A
(en)
*
|
2012-11-28 |
2019-03-29 |
Intercept Pharmaceuticals Inc |
Treatment of pulmonary disease
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
SI2986624T1
(sl)
|
2013-04-17 |
2020-10-30 |
Sage Therapeutics, Inc. |
19-nor nevroaktivni steroidi za metode zdravljenja
|
|
EP2986623B1
(en)
|
2013-04-17 |
2018-11-07 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
|
|
SI3021852T1
(sl)
|
2013-07-19 |
2021-07-30 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, sestavki in uporabe le-teh
|
|
JP6466942B2
(ja)
|
2013-08-23 |
2019-02-06 |
セージ セラピューティクス， インコーポレイテッド |
向神経活性ステロイド、組成物、及びその使用
|
|
EP3149156B1
(en)
|
2014-05-28 |
2021-02-17 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
LT3149019T
(lt)
|
2014-05-29 |
2020-02-25 |
Bar Pharmaceuticals S.R.L. |
Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai
|
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
CN106459136B
(zh)
*
|
2014-09-28 |
2018-06-26 |
江苏盛迪医药有限公司 |
一种奥贝胆酸的制备方法
|
|
EP4527461A3
(en)
|
2014-10-16 |
2025-06-25 |
Sage Therapeutics, Inc. |
A compound, compositions thereof and this compound for use in methods of treating cns disorders
|
|
RS60642B1
(sr)
|
2014-10-16 |
2020-09-30 |
Sage Therapeutics Inc |
Kompozicije i postupci za lečenje poremećaja cns-a
|
|
US11584916B2
(en)
|
2014-10-17 |
2023-02-21 |
Children's Hospital Medical Center |
Method of making in vivo human small intestine organoids from pluripotent stem cells
|
|
EP3215179A4
(en)
|
2014-11-06 |
2018-07-25 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
WO2016079517A1
(en)
|
2014-11-19 |
2016-05-26 |
Dextra Laboratories Limited |
6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
|
|
EA033603B1
(ru)
|
2014-11-19 |
2019-11-08 |
Nzp Uk Ltd |
6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
EA033445B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
WO2016079519A1
(en)
*
|
2014-11-19 |
2016-05-26 |
Dextra Laboratories Limited |
6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
|
|
JP2017535570A
(ja)
|
2014-11-26 |
2017-11-30 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
SMT202000276T1
(it)
|
2014-11-27 |
2020-07-08 |
Sage Therapeutics Inc |
Composizioni e metodi per trattare disturbi del snc
|
|
CN105777835B
(zh)
*
|
2014-12-25 |
2020-02-14 |
重庆药友制药有限责任公司 |
一种制备鹅去氧胆酸类似物的方法
|
|
CN105801653B
(zh)
|
2014-12-30 |
2018-04-17 |
苏州晶云药物科技有限公司 |
奥贝胆酸的晶型a及其制备方法
|
|
CN105859814A
(zh)
*
|
2015-01-23 |
2016-08-17 |
江苏奥赛康药业股份有限公司 |
一种奥贝胆酸化合物及其药物组合物
|
|
SMT202100113T1
(it)
|
2015-01-26 |
2021-05-07 |
Sage Therapeutics Inc |
Composizioni e metodi per trattare disturbi del snc
|
|
EA036404B1
(ru)
|
2015-02-06 |
2020-11-06 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции для комбинированной терапии
|
|
MX2017010376A
(es)
|
2015-02-11 |
2017-12-20 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
|
|
CN105985395A
(zh)
*
|
2015-02-13 |
2016-10-05 |
江苏奥赛康药业股份有限公司 |
一种奥贝胆酸化合物及含有该化合物的药物组合物
|
|
CN105985396A
(zh)
*
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
|
JP6875996B2
(ja)
|
2015-02-20 |
2021-05-26 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド、組成物、およびその使用
|
|
MX2017011399A
(es)
*
|
2015-03-09 |
2018-03-16 |
Intercept Pharmaceuticals Inc |
Métodos para modular la densidad ósea.
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
EA036757B1
(ru)
|
2015-04-07 |
2020-12-17 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции для комбинированной терапии
|
|
CN105777836A
(zh)
*
|
2015-04-09 |
2016-07-20 |
厦门蔚扬药业有限公司 |
奥贝胆酸的多晶型物及其制备方法
|
|
WO2016168553A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Concert Pharmaceuticals, Inc. |
Deuterated obeticholic acid
|
|
PE20180690A1
(es)
*
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
CN106290594B
(zh)
*
|
2015-05-27 |
2020-07-17 |
中美华世通生物医药科技（武汉）有限公司 |
测定奥贝胆酸片溶出含量的方法
|
|
CN105294801A
(zh)
*
|
2015-07-02 |
2016-02-03 |
扬子江药业集团南京海陵药业有限公司 |
6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
|
|
CZ2015504A3
(cs)
|
2015-07-16 |
2017-01-25 |
Zentiva, K.S. |
Krystalické formy obeticholové kyseliny
|
|
EP3124080A1
(en)
*
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
CN105085597B
(zh)
*
|
2015-08-28 |
2017-03-29 |
成都百裕制药股份有限公司 |
一种无定型奥贝胆酸的制备方法
|
|
CN106478756A
(zh)
*
|
2015-09-02 |
2017-03-08 |
中美华世通生物医药科技（武汉）有限公司 |
Oca-e单晶及其制备方法和用途
|
|
CA2998876A1
(en)
*
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
KR20180052756A
(ko)
|
2015-09-24 |
2018-05-18 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체 제조를 위한 방법 및 중간체
|
|
DK3359160T3
(da)
|
2015-10-07 |
2021-11-22 |
Intercept Pharmaceuticals Inc |
Farnesoid x receptor modulatorer
|
|
CN106589038A
(zh)
*
|
2015-10-15 |
2017-04-26 |
重庆医药工业研究院有限责任公司 |
一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
|
|
CN106589039B
(zh)
*
|
2015-10-15 |
2019-12-17 |
苏州朗科生物技术股份有限公司 |
一种奥贝胆酸的制备方法及相关化合物
|
|
CN106632564B
(zh)
*
|
2015-10-30 |
2021-04-13 |
苏州泽璟生物制药股份有限公司 |
奥贝胆酸盐及其无定形物和药物组合物
|
|
CN106668027A
(zh)
*
|
2015-11-05 |
2017-05-17 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸药物组合物及其制备方法
|
|
WO2017079062A1
(en)
*
|
2015-11-06 |
2017-05-11 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
|
CN106749466B
(zh)
*
|
2015-11-23 |
2019-05-21 |
南京济群医药科技股份有限公司 |
一种高纯度奥贝胆酸的制备方法
|
|
CN105315320B
(zh)
*
|
2015-11-30 |
2017-03-08 |
山东省药学科学院 |
一种制备奥贝胆酸的方法
|
|
CN106810587A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技（武汉）有限公司 |
制备无定型奥贝胆酸的方法
|
|
CN106810586A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸晶型ⅱ及其制备方法和用途
|
|
CN106822005A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏先声药业有限公司 |
奥贝胆酸组合物及其制备方法
|
|
CN106854229A
(zh)
*
|
2015-12-08 |
2017-06-16 |
陈剑 |
一类脂肪酸盐,其制备及其在医药上的应用
|
|
CN105481925B
(zh)
*
|
2015-12-17 |
2018-06-22 |
南京济群医药科技股份有限公司 |
一种奥贝胆酸及其中间体的制备方法
|
|
AU2016375566A1
(en)
*
|
2015-12-22 |
2018-07-05 |
Intercept Pharmaceuticals, Inc. |
Polymorphic crystalline forms of obeticholic acid
|
|
CN105399793A
(zh)
*
|
2015-12-24 |
2016-03-16 |
北京康立生医药技术开发有限公司 |
一种胆烷酸的制备方法
|
|
CN106916195A
(zh)
*
|
2015-12-25 |
2017-07-04 |
中美华世通生物医药科技（武汉）有限公司 |
奥贝胆酸中间体的纯化方法
|
|
WO2017115324A1
(en)
*
|
2016-01-01 |
2017-07-06 |
Lupin Limited |
Solid forms of obeticholic acid and processes thereof
|
|
CN105566429B
(zh)
*
|
2016-01-22 |
2020-12-01 |
南京长澳医药科技有限公司 |
一种奥贝胆酸1型的制备方法
|
|
CN105646633B
(zh)
*
|
2016-01-22 |
2020-05-26 |
南京长澳医药科技有限公司 |
一种制备奥贝胆酸1型的方法
|
|
CN105646634A
(zh)
*
|
2016-01-29 |
2016-06-08 |
中国药科大学 |
奥贝胆酸杂质的制备方法
|
|
US10519193B2
(en)
|
2016-02-02 |
2019-12-31 |
Shenzhen Targetrx, Inc. |
Steroidal compound, composition containing the same and use thereof
|
|
WO2017136617A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Cinrx Pharma, Llc |
Deuterated domperidone compositions and methods for therapy of disorders
|
|
EP3414256B1
(en)
*
|
2016-02-10 |
2022-01-19 |
Dr. Reddy's Laboratories Limited |
Purification process involving amine salt of obeticholic acid
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10323061B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
|
CN107126419B
(zh)
*
|
2016-02-26 |
2020-06-19 |
石药集团中诺药业（石家庄）有限公司 |
一种奥贝胆酸片剂及其制备方法
|
|
CN106008639B
(zh)
*
|
2016-03-11 |
2019-01-08 |
深圳市塔吉瑞生物医药有限公司 |
用于预防或治疗fxr-介导疾病的胆烷酸化合物
|
|
CN105541953B
(zh)
*
|
2016-03-15 |
2017-11-21 |
成都市新功生物科技有限公司 |
一种高纯度奥贝胆酸的重结晶纯化方法
|
|
CN107188917A
(zh)
*
|
2016-03-15 |
2017-09-22 |
正大天晴药业集团股份有限公司 |
奥贝胆酸盐及其药物组合物
|
|
EP3437659B1
(en)
*
|
2016-03-28 |
2023-03-01 |
Intercept Pharmaceuticals, Inc. |
Combination of a fxr agonist and an angiotensin ii receptor blocker
|
|
TW201735928A
(zh)
|
2016-03-31 |
2017-10-16 |
大日本住友製藥股份有限公司 |
溶出性優異之口服製劑
|
|
WO2017167233A1
(zh)
*
|
2016-03-31 |
2017-10-05 |
江苏恒瑞医药股份有限公司 |
一种奥贝胆酸的新结晶形式及其制备方法
|
|
WO2017170854A1
(ja)
|
2016-03-31 |
2017-10-05 |
大日本住友製薬株式会社 |
有効成分の化学的安定性に優れたフィルムコーティング錠
|
|
EP3228306A1
(en)
|
2016-04-04 |
2017-10-11 |
ratiopharm GmbH |
Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
|
|
EP3440092A1
(en)
|
2016-04-04 |
2019-02-13 |
Dipharma Francis S.r.l. |
Method for preparing a farnesoid x receptor agonist
|
|
TW201738254A
(zh)
*
|
2016-04-19 |
2017-11-01 |
英特賽普醫藥品公司 |
奧貝膽酸及其衍生物之製備方法
|
|
CN116790476A
(zh)
|
2016-05-05 |
2023-09-22 |
儿童医院医疗中心 |
用于体外制造胃底组织的方法和与其相关的组合物
|
|
CN105859817A
(zh)
*
|
2016-05-09 |
2016-08-17 |
成都宇西医药技术有限公司 |
一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
CN107400154A
(zh)
*
|
2016-05-18 |
2017-11-28 |
北京凯因科技股份有限公司 |
一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
|
|
CN106046094A
(zh)
*
|
2016-05-30 |
2016-10-26 |
福建广生堂药业股份有限公司 |
一种奥贝胆酸二聚体杂质及其制备方法
|
|
CN105859818A
(zh)
*
|
2016-05-31 |
2016-08-17 |
四川瑞希康生物医药有限公司 |
一种奥贝胆酸α晶型及其制备方法、药物组合物和用途
|
|
US10875887B2
(en)
|
2016-06-01 |
2020-12-29 |
Dr. Reddy's Laboratories Limited. |
Process for preparation of obeticholic acid
|
|
CN105997909A
(zh)
*
|
2016-06-02 |
2016-10-12 |
中国药科大学 |
一种奥贝胆酸口崩片及其制备方法
|
|
WO2017218337A1
(en)
|
2016-06-13 |
2017-12-21 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
CN106083971B
(zh)
*
|
2016-06-17 |
2017-11-14 |
苏州敬业医药化工有限公司 |
一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
|
|
CZ2016385A3
(cs)
|
2016-06-28 |
2018-01-10 |
Zentiva, K.S. |
Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
|
|
CN107540720B
(zh)
*
|
2016-06-29 |
2021-03-02 |
常州市第四制药厂有限公司 |
3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用
|
|
IL264129B2
(en)
|
2016-07-11 |
2024-05-01 |
Sage Therapeutics Inc |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
|
NZ790187A
(en)
|
2016-07-11 |
2025-08-29 |
Sage Therapeutics Inc |
C7, C12, and C16 substituted neuroactive steroids and their methods of use
|
|
CN107648190B
(zh)
*
|
2016-07-26 |
2021-04-27 |
海南先声药业有限公司 |
奥贝胆酸组合物及其制备方法
|
|
CN106279331B
(zh)
*
|
2016-07-27 |
2019-06-14 |
宋火良 |
胆酸类肝病治疗药物
|
|
CN107674106B
(zh)
*
|
2016-08-01 |
2021-06-22 |
华北制药集团新药研究开发有限责任公司 |
一种奥贝胆酸二聚体的制备方法
|
|
CN106279335A
(zh)
*
|
2016-08-12 |
2017-01-04 |
齐鲁制药有限公司 |
一种制备奥贝胆酸及其中间体的方法
|
|
EP3287467A1
(en)
|
2016-08-22 |
2018-02-28 |
ratiopharm GmbH |
Preparation of obeticholic acid comprising continuous flow process steps
|
|
CN107793463A
(zh)
*
|
2016-08-29 |
2018-03-13 |
鲁南制药集团股份有限公司 |
一种3α‑羟基‑6α‑乙基‑7‑酮‑5β‑胆‑24‑酸的制备方法
|
|
CN107778339A
(zh)
*
|
2016-08-29 |
2018-03-09 |
鲁南制药集团股份有限公司 |
一种无定型奥贝胆酸的制备方法
|
|
EP3293196A1
(en)
|
2016-09-09 |
2018-03-14 |
Hexal AG |
Process for purifying obeticholic acid
|
|
CN106478757B
(zh)
*
|
2016-09-27 |
2019-01-18 |
华南理工大学 |
一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
|
|
BR112019006242A2
(pt)
*
|
2016-09-30 |
2019-06-18 |
Intercept Pharmaceuticals Inc |
formas cristalinas de um derivado de ácido biliar
|
|
CN107976506B
(zh)
*
|
2016-10-25 |
2020-05-12 |
成都弘达药业有限公司 |
一种奥贝胆酸有关物质的检测方法
|
|
KR102546194B1
(ko)
|
2016-11-04 |
2023-06-21 |
칠드런즈 호스피탈 메디칼 센터 |
간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
|
|
KR102499441B1
(ko)
|
2016-11-29 |
2023-02-13 |
이난타 파마슈티칼스, 인코포레이티드 |
술포닐우레아 담즙산 유도체의 제조 방법
|
|
KR102558606B1
(ko)
|
2016-12-05 |
2023-07-26 |
칠드런즈 호스피탈 메디칼 센터 |
결장 유사장기 및 이를 제조 및 사용하는 방법
|
|
EP3551180B1
(en)
*
|
2016-12-09 |
2021-09-29 |
Cadila Healthcare Limited |
Treatment for primary biliary cholangitis
|
|
CN108614038B
(zh)
*
|
2016-12-13 |
2022-05-17 |
亚宝药业集团股份有限公司 |
一种测定奥贝胆酸原料药有关物质的方法
|
|
CN106749472B
(zh)
*
|
2016-12-30 |
2019-02-22 |
江苏开元医药化工有限公司 |
一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法
|
|
CN106645497A
(zh)
*
|
2017-01-03 |
2017-05-10 |
山东省药学科学院 |
一种奥贝胆酸及其制剂中有关物质的检测方法
|
|
KR20190103327A
(ko)
|
2017-01-18 |
2019-09-04 |
트렘코 인코포레이티드 |
구조용 접합 복합재
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
CN106892954B
(zh)
*
|
2017-02-23 |
2019-04-30 |
广州隽沐生物科技有限公司 |
奥贝胆酸的制备工艺
|
|
JP2020514337A
(ja)
*
|
2017-03-08 |
2020-05-21 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
オベチコール酸の結晶形態
|
|
SI3600309T1
(sl)
|
2017-03-28 |
2022-10-28 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
CN108659086A
(zh)
*
|
2017-03-29 |
2018-10-16 |
杭州源昶医药科技有限公司 |
一种奥贝胆酸的合成方法
|
|
US10676500B2
(en)
|
2017-04-07 |
2020-06-09 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonyl carbamate bile acid derivatives
|
|
WO2018191673A1
(en)
|
2017-04-14 |
2018-10-18 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
CN106986910A
(zh)
*
|
2017-04-19 |
2017-07-28 |
成都百特万合医药科技有限公司 |
奥贝胆酸中间体的制备方法
|
|
US11053275B2
(en)
|
2017-04-20 |
2021-07-06 |
Daewoong Bio Inc. |
Method for bile acid derivative by using continuous flow reaction
|
|
WO2018211413A1
(en)
*
|
2017-05-15 |
2018-11-22 |
Dr. Reddy’S Laboratories Limited |
Solid forms of obeticholic acid and process for preparation
|
|
CZ2017298A3
(cs)
|
2017-05-26 |
2018-12-05 |
Zentiva, K.S. |
Amorfní formy obeticholové kyseliny
|
|
CN107286160A
(zh)
*
|
2017-06-05 |
2017-10-24 |
毛佳婧 |
一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
|
|
KR20240125702A
(ko)
|
2017-06-30 |
2024-08-19 |
신돔 파마, 인크. |
중수소화 돔페리돈 조성물, 방법, 및 제조
|
|
US12478612B2
(en)
|
2017-06-30 |
2025-11-25 |
Cindome Pharma, Inc. |
Deuterated domperidone compositions, methods, and preparation
|
|
CN109280071A
(zh)
*
|
2017-07-19 |
2019-01-29 |
东莞东阳光药物研发有限公司 |
奥贝胆酸的晶型及其制备方法
|
|
AU2018307611A1
(en)
|
2017-07-24 |
2020-02-06 |
Intercept Pharmaceuticals, Inc. |
Isotopically labeled bile acid derivatives
|
|
JP6937893B2
(ja)
|
2017-08-03 |
2021-09-22 |
メディトックス インク． |
胆汁酸類を製造するための方法
|
|
CN107383139A
(zh)
*
|
2017-08-09 |
2017-11-24 |
杭州和泽医药科技有限公司 |
一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
|
|
CN109485687A
(zh)
*
|
2017-09-12 |
2019-03-19 |
成都弘达药业有限公司 |
奥贝胆酸的晶型j及其制备方法
|
|
EP3694603A4
(en)
|
2017-10-10 |
2021-07-14 |
Children's Hospital Medical Center |
ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
|
|
US10611793B1
(en)
|
2017-11-27 |
2020-04-07 |
Teva Czech Industries S.R.O. |
Solid state forms of obeticholic acid salts
|
|
WO2019106043A1
(en)
|
2017-11-29 |
2019-06-06 |
Hexal Ag |
Pharmaceutical composition comprising obeticholic acid
|
|
WO2019113494A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Sage Therapeutics, Inc. |
Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
US11434256B2
(en)
|
2018-01-25 |
2022-09-06 |
Msn Laboratories Private Limited, R&D Center |
Process for the preparation of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid
|
|
CN108440629A
(zh)
*
|
2018-03-16 |
2018-08-24 |
丽珠集团新北江制药股份有限公司 |
一种制备奥贝胆酸中间体及奥贝胆酸的方法
|
|
WO2019197962A1
(en)
*
|
2018-04-09 |
2019-10-17 |
Biophore India Pharmaceuticals Pvt. Ltd |
Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
|
|
CN110655550A
(zh)
*
|
2018-06-29 |
2020-01-07 |
江苏海悦康医药科技有限公司 |
(E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
|
|
CN108794558B
(zh)
*
|
2018-07-03 |
2020-05-22 |
丽珠集团新北江制药股份有限公司 |
一种反应条件温和的奥贝胆酸制备方法
|
|
JP7506657B2
(ja)
|
2018-07-26 |
2024-06-26 |
チルドレンズ ホスピタル メディカル センター |
肝胆膵組織およびその作製方法
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US20210261599A1
(en)
*
|
2018-08-24 |
2021-08-26 |
Solara Active Pharma Sciences Limited |
Process for the Preparation of Obeticholic Acid and Intermediates Used In the Process Thereof
|
|
US12428622B2
(en)
|
2018-09-12 |
2025-09-30 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
JP2022506782A
(ja)
*
|
2018-11-08 |
2022-01-17 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
オベチコール酸の使用方法
|
|
CN109535217B
(zh)
*
|
2018-11-13 |
2020-04-14 |
丽珠集团新北江制药股份有限公司 |
一种奥贝胆酸的精制方法
|
|
WO2020150136A1
(en)
|
2019-01-15 |
2020-07-23 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
|
US11524005B2
(en)
|
2019-02-19 |
2022-12-13 |
Gilead Sciences, Inc. |
Solid forms of FXR agonists
|
|
CA3142358A1
(en)
|
2019-05-30 |
2020-12-03 |
Intercept Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
|
|
JP7610533B2
(ja)
|
2019-05-31 |
2025-01-08 |
チルドレンズ ホスピタル メディカル センター |
造血幹細胞の生成および拡大方法
|
|
SG11202112391UA
(en)
|
2019-05-31 |
2021-12-30 |
Sage Therapeutics Inc |
Neuroactive steroids and compositions thereof
|
|
WO2021029656A1
(ko)
*
|
2019-08-14 |
2021-02-18 |
주식회사 바이오톡스텍 |
하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
|
|
CN112824425B
(zh)
*
|
2019-11-21 |
2023-10-03 |
成都西岭源药业有限公司 |
一种6-位烯基取代胆酸化合物及其制备方法和应用
|
|
US20230201222A1
(en)
*
|
2020-05-13 |
2023-06-29 |
Children's Hospital Medical Center |
Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
|
|
WO2022051321A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a fxr agonist
|
|
KR102526452B1
(ko)
*
|
2020-10-28 |
2023-04-27 |
(주)델로 |
관절 구조를 포함하는 토이 로봇
|
|
CN114644670A
(zh)
*
|
2020-12-17 |
2022-06-21 |
四川弘远药业有限公司 |
奥贝胆酸和对氨基苯甲酸的共晶及其制备方法
|
|
CN114236027B
(zh)
*
|
2021-12-22 |
2024-01-12 |
中山百灵生物技术股份有限公司 |
一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法
|
|
US12343351B2
(en)
|
2022-03-25 |
2025-07-01 |
Rutgers, The State University Of New Jersey |
Pulmonary function treatment
|